Overview
Talus Bio is an innovative biotechnology firm headquartered at 550 17th Ave, Suite 550, Seattle, WA 98122. Specializing in drug development targeting transcription factors previously considered "undruggable," the company utilizes cutting-edge technologies, including functional proteomics, automated biology, and machine learning. Their primary focus is on treating major diseases such as cancer and diabetes by targeting the transcription factors driving these conditions.
Leadership and Team
- Alex Federation, Ph.D.: Serving as the Chief Executive Officer and Co-Founder, he crafts and executes the strategic vision of Talus Bio.
- Lindsay Pino, Ph.D.: As Chief Technology Officer and Co-Founder, she spearheads the development of the MARMOT platform crucial for drug discovery.
- Michelle Briscoe: Dual tasking as the Chief Operating Officer and Chief Financial Officer, she fosters an inclusive working environment.
- Christopher Joyce, MBA: The newly appointed Vice President of Business Development, he focuses on forging pharmaceutical partnerships and expanding commercial reach.
- Gaelle Mercenne, Ph.D.: The Head of Biology manages preclinical development using proprietary platforms.
- The team also features experts like Will Fondrie, Ph.D., and Kyle Siebenthall, Ph.D., reinforcing Talus Bio's data science, biology, and strategic operations.
Business and Technological Advancements
Talus Bio's pioneering MARMOT platform offers unique insights into transcription factors within human cellular environments.
Financial Performance
- Annual Revenue: Approximately $1.8 million
- Significant funding includes:
- $11.2 million in new funds for AI-based drug discovery.
- Accumulated funding totals $19.7 million sourced from investors, including Two Bear Capital and Y Combinator.
- A $4.3 million grant fuels research into pediatric cancer therapeutics.
Recent Developments and Industry Engagement
Talus Bio actively seeks novel therapeutic opportunities, evidenced by its significant grants for pediatric cancer research. The company remains visible within scientific circles via LinkedIn updates and conference participations.
Contact Information
For further inquiries, Talus Bio can be contacted via info@talus.bio or phone at (206) 487-1062. More information is available on their website: [talus.bio](https://talus.bio/).
Competitive Landscape
Key Competitors
Talus Bio navigates a competitive landscape comprising notable biotechnology entities:
1. 10x Genomics
2. Amgen
3. Biogen
4. Aro Biotherapeutics
5. Carisma Therapeutics
6. Verismo Therapeutics
7. Resolve BioSciences
8. Viridos
9. Octant Bio
10. VectorBuilder
11. Proteomyx
12. Abilita Bio
These competitors largely engage in biotech and drug development fields, focusing on innovative cancer treatments and gene regulatory proteins.
Notable Competitors
Octant Bio
- Focus: Harnessing synthetic biology for small molecule therapeutics.
- Key Technologies: Barcoded multiplexing, AI/ML pipelines.
- Funding: $115 million across several rounds.
Resolve BioSciences
- Technology: Molecular Cartography™ for biological analysis.
- Base: Monheim am Rhein, Germany.
Unity Biotechnology
- Specialization: Targeting cellular senescence in aging-related diseases.
- Stock: Priced at $1.73 per share with a market cap of $28.8 million.
Altos Labs
- Mission: Cell rejuvenation for disease and aging reversal.
- Approach: Synergizes academic and industrial methodologies.
Strategic Considerations
To bolster its competitive advantage, Talus Bio should focus on:
- Continued innovation in gene regulatory drug development.
- Expansion into rare diseases and oncology to meet the demand for personalized treatments.
- Establishment of partnerships and collaborative ventures to enhance technological strength.
- Securing additional funding to support R&D and operational expansion.
By steadfastly pursuing research and development, Talus Bio aims to establish a substantial presence in the ever-evolving biotechnology sector.
